USPTO serial 79366890
FOLDIKINE
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Mar 26, 2024
- Examiner
- MORRIS, KRISTINA KLOIBER
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
Need help with FOLDIKINE?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
FUNDACIÓ CENTRE DE REGULACIÓ GENÒMICA
ES
Other trademarks owned by FUNDACIÓ CENTRE DE REGULACIÓ GENÒMICA
FUNDACIÓ CENTRE DE REGULACIÓ GENÒMICA
ES
Other trademarks owned by FUNDACIÓ CENTRE DE REGULACIÓ GENÒMICA
FUNDACIÓ CENTRE DE REGULACIÓ GENÒMICA
ES
Other trademarks owned by FUNDACIÓ CENTRE DE REGULACIÓ GENÒMICA
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Stephanie N. Nikitenko
Stephanie N. Nikitenko IpHorgan Ltd195 Arlington Heights Rd, Suite #125Buffalo Grove, IL 60089UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | Protein in raw material form for scientific and medical research; proteins for use in science; proteins for use in industry; proteins for use in the manufacture of cosmetics; biological preparations for industry and science; biological preparations for use in the manufacture of cosmetics; immunomodulatory biological molecules and chimeras thereof for scientific use, other than for medical or veterinary use; immunomodulatory biological molecules and chimeras thereof for industrial use, other than for medical or veterinary use; immunomodulatory biological molecules and chimeras thereof for use in the manufacture of cosmetics; immunomodulatory biological molecules and chimeras thereof for use in laboratories, other than for medical or veterinary use; culture media for microbiology for scientific and research use; culture media of eukaryotic cells, in particular, immune, lymphoid and myeloid cells for scientific and research use | ACTIVE | — |
| 005 | Pharmaceutical preparations for the treatment of immune-mediated diseases; veterinary preparations for the treatment of immune-mediated diseases; biological preparations for medical use for the treatment of immune-mediated diseases; biological preparations for veterinary purposes for the treatment of immune-mediated diseases; immunomodulators; immunosuppressants; immunostimulants; growth factors, namely, cell growth media for growing cells for medical or clinical use; cell survival factors, namely cell growth media for growing cells for medical or clinical use; pharmaceutical and veterinary preparations for regulating the immune system; pharmaceutical and veterinary preparations for the treatment and/or prevention of diseases and disorders of the immune system or those affecting the immune system; regulatory proteins for medical and veterinary use in the nature of protein arrays for medical use and medical diagnosis purposes | ACTIVE | — |
| 042 | Scientific and technological services, namely, scientific research ; research and development of products; design and development of biological, pharmaceutical and veterinary products; medical, pharmacological and veterinary research services; research related to molecular science; research and development services in immunology; research and development services in the field of immunohistology; research and development services with respect to immunomodulatory molecules; laboratory research services in relation to the production of immunomodulatory biological molecules and chimeras thereof; software design and development; information, advisory, and consultancy relating to the aforesaid services | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by FUNDACIÓ CENTRE DE REGULACIÓ GENÒMICA
- Other trademarks owned by FUNDACIÓ CENTRE DE REGULACIÓ GENÒMICA
- Other trademarks owned by FUNDACIÓ CENTRE DE REGULACIÓ GENÒMICA
- Other trademarks in Class 001
- Other trademarks in Class 005
- Other trademarks in Class 042
- Similar marks named FOLDIKINE
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Dec 21, 2024 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Nov 15, 2024 | XXSS | GENERIC MADRID TRANSACTION SENT TO IB | — |
| Nov 14, 2024 | XXCR | GENERIC MADRID TRANSACTION CREATED | — |
| Jun 27, 2024 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Mar 26, 2024 | NRCC | NOTICE OF REGISTRATION CONFIRMATION EMAILED | — |
| Mar 26, 2024 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Jan 9, 2024 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Jan 9, 2024 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Jan 8, 2024 | GPNX | NOTIFICATION PROCESSED BY IB | — |
| Dec 20, 2023 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Dec 20, 2023 | OP2R | NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB | — |
| Dec 20, 2023 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Nov 29, 2023 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Nov 14, 2023 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Nov 14, 2023 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Nov 14, 2023 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Oct 25, 2023 | RFNT | REFUSAL PROCESSED BY IB | — |
| Oct 3, 2023 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Oct 3, 2023 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Sep 21, 2023 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Sep 20, 2023 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Sep 13, 2023 | DOCK | ASSIGNED TO EXAMINER | — |
| Apr 14, 2023 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Apr 10, 2023 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Apr 6, 2023 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |